Hypertension
Conditions
Keywords
CKD-828, Hypertension, Primary Hypertension, S-Amlodipine, Telmisartan, Non-Responder
Brief summary
The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg) in hypertensive patients inadequately controlled by S-Amlodipine monotherapy.
Detailed description
* In patients with essential hypertension inadequately controlled by S-Amlodipine monotherapy to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg)during 8weeks. * Included S-Amlodipine run-in period(during 4 weeks\_single blind) and Treatment period(during 8 weeks\_double blind).
Interventions
DRUGCKD-828 2.5/40mg
fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
DRUGCKD-828 2.5/80mg
Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
S-Amlodipine 2.5mg monotherapy
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age 18 years or older * diagnosis of essential hypertension and blood pressure not adequately controlled (inadequate control defined as seated diastolic blood pressure(DBP)≥ 90mmHg if on existing amtihypertensive treatment of seated DBP≥100mmHg if treatment naive) * failure to respond to four weeks treatment with S-Amlodipine 2.5mg(failure to respond defined as seated DBP ≥ 90mmHg) * willing and able to provide written informed consent
Exclusion criteria
* mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 200mmHg during run-in treatment or mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 180mmHg at the randomization visit * known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma) * has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months * has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months * Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) \> 8% * known severe or malignant retinopathy * hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT \> UNL X 2, serum creatinine \> UNL X 1.5 * acute or chronic inflammatory status need to treatment * need to additional antihypertensive drugs during the study * need to concomitant medications known to affect blood pressure during the study * history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers * known hypersensitivity related to either study drug * history of drug or alcohol dependency within 6 months * any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding * administration of other study drugs within 30 days prior to randomization * premenopausal women(last menstruation \< 1year) not using adequate contraception, pregnant or breast-feeding * history of malignancy including leukemia and lymphoma within the past 5 years * in investigator's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Sitting Diastolic Blood Pressure (MSDBP) | After 8 weeks of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Sitting Diastolic Blood Pressure (MSDBP) | After 4 weeks of treatment | — |
| Mean Sitting Systolic Blood Pressure (MSSBP) | After 4 weeks and 8 weeks of treatment | — |
| Control Rate | After 8 weeks of treatment | SBP\<140mmHg, DBP\<90mmHg |
| Response Rate | After 8 weeks of treatment | Reduction of SBP≥20mmHg, DBP≥10mmHg |
Countries
South Korea
Outcome results
None listed